PRESS RELEASE

Paris and Toulouse, March 11, 2014

# GENTICEL ANNOUNCES THE REGISTRATION OF ITS " DOCUMENT DE BASE" IN THE CONTEXT OF THE COMPANY'S CONTEMPLATED INITIAL PUBLIC OFFERING ON THE EURONEXT PARIS AND BRUSSELS REGULATED MARKETS

French biotechnology company GENTICEL, a leading developer of therapeutic vaccines, announces in the context of its contemplated Initial Public Offering, the registration of its Document de Base by the French Markets Authority (AMF) under number I.14-007 on March 10, 2014.

The registration of the 'Document de Base' is the first step towards GENTICEL's initial public offering of its shares on the regulated market Euronext in Paris and in Brussels. *(The process is subject to market conditions and to the AMF VISA on the prospectus for the transaction and* ***notified to the FSMA in Belgium in compliance with the European passport procedure of Directive 2003/71/EU).***

## A portfolio of therapeutic vaccines in development, to reduce the frequency of cervical cancer

Founded around a scientific innovation from the Pasteur Institute, GENTICEL is a leading specialist in developing therapeutic vaccines. In contrast to preventive vaccines prescribed before infection, "therapeutic" vaccines are designed to treat people who are already infected. They work by activating the immune system specifically against the transformed cells, for example during the course of a viral infection or a developing cancer.

The therapeutic vaccine candidates developed by GENTICEL are designed to eliminate, at an early stage, the cells carrying the human papillomavirus (HPV), the agent responsible for cervical cancer, one of the most widespread cancers in women worldwide. To date, there is no registered drug available for the 93 million women around the world who carry the most dangerous HPV viruses but do not yet display high grade lesions or cervical cancer.

GENTICEL's goal is to sharply reduce the frequency of cervical cancer, thus addressing a serious public health problem. Every year, 500,000 women around the world develop this cancer and 275,000 of them die from it.

## ProCervix, a “first-in-class” therapeutic vaccine candidate with blockbuster potential, now in Phase II

Based on the promising results of Phase I trials endorsed by an international group of experts, Genticel has started a phase II study in Europe with its lead product ProCervix, a “first-in-class” therapeutic vaccine.

ProCervix is designed to eradicate the HPV16 and/or HPV18 viruses before high-grade lesions or cancer occur. 93 million women carry HPV 16 and/or HPV 18 which, together, are responsible for 70% of cervical cancers worldwide.

Preventive HPV vaccines are only effective in people who are not yet infected by the virus. Currently, the only option that already infected women have, is to wait and have more frequent check-ups until a natural clearance of the infection occurs or until it develops into high grade lesions that require surgery. High grade lesions are commonly removed by conisation and in certain cases by more aggressive ablation procedures including hysterectomy; cervical cancer is treated by various combination treatments including chemo and radiotherapy.

The goal of the ProCervix project is to fill this therapeutic gap and, for the first time ever, to be able to treat this high-risk population.

As a conservative estimate, ProCervix could be prescribed to 1.3 million women a year and achieve peak sales of over €1 billion.

## Also a “best-in-class” therapeutic vaccine candidate in development.

GENTICEL is also developing a second therapeutic vaccine candidate, Multivalent HPV, currently in preclinical phase, that targets six of the most pertinent types of HPV virus, including HPV16 and HPV18, in terms of worldwide epidemiology. This “best-in-class” therapeutic vaccine candidate has an even broader coverage, potentially effective for 158 million women worldwide and targeting 85% of cervical cancers.

## Partnerships envisaged for the portfolio of therapeutic vaccines...

GENTICEL's strategy includes establishing a partnership with a major pharmaceutical laboratory to valorise its portfolio of candidate therapeutic HPV vaccines in the years to come, in particular with the view to run Phase III trials with ProCervix in the United States and Europe and have it marketed worldwide.

## ...and for the Vaxiclase platform beyond HPV

GENTICEL has developed Vaxiclase, a new-generation platform to deliver antigens. The company owns the entire intellectual property for this technology.

The Vaxiclase platform is ideally adapted to develop early-intervention immunotherapies to combat infectious or cancerous diseases. These opportunities will be explored through partnerships with pharmaceutical companies.

## A proposed IPO to fund value creation

The proposed Initial Public Offering (IPO) on the Euronext Paris and Brussels regulated markets should give the Company the financial resources to continue developing its therapeutic vaccines. The development focuses on completing the ProCervix Phase II trial in Europe and to begin a Phase I study in the United States with the objective to enter coordinated Phase III trials in both geographical regions.

## Availability of the "Document de Base "

Copies of the "Document de Base" registered on March 10, 2014 under number I.14-007 are available, free of charge on request, from Genticel's registered office – Prologue Biotech, 516 rue Pierre et Marie Curie – 31670 Labège – Innopôle – France. It is also available on Genticel's website (www.genticel-bourse.com) and the website of the French Financial Markets Authority (AMF) (www.amf-france.org).

## Risk factors

The public's attention is drawn to Section 4 "Risk Factors" of the "Document de Base" registered by the AMF.

### *About Genticel*

*GENTICEL is a French pharmaceutical company, specialising in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.*
*GENTICEL is developing the first-ever therapeutic vaccine, currently in Phase II clinical trials, aimed at eliminating cervical cells infected by type 16 and/or 18 HPV virus. A second therapeutic vaccine candidate targeting six of the most pertinent strains of HPV is currently in preclinical stage. Over many years of R&D, the Company also has a technological platform, Vaxiclase, ideally adapted for developing early-intervention immunotherapies against multiple infectious or cancerous diseases.*
*Based in Paris and Toulouse, Genticel was awarded the 2013 Innovation Prize by the Grands Prix de l'Economie.*

*For more information go to www.genticel-bourse.com*


| GENTICEL CONTACT | INVESTORS CONTACT | PRESS CONTACT |
|---|---|---|
| Benedikt Timmerman<br>Chief Executive Officer<br>investors@genticel.com | Corinne Puissant<br>Edouard de Maissin<br><br>Tel: +33 (0)1 53 67 36 57<br>genticel@actus.fr | Alexandra Prisa<br><br>Tel: +33 (0)1 53 67 35 79<br>aprisa@actus.fr |



## Disclaimer

This communcation and the information in it do not constitute an offer to buy or subscribe, or an encouragement to buy or subscribe, to shares in Genticel in any country. No offer can be made now or in the future without the prior approval by the French Financial Markets Authority (*Autorité des Marchés Financiers* or "AMF") of a prospectus that consists of the Base Document (*document de base*) which is the subject of this communication and a Securities Note (*note d'opération*) subsequently submitted to the AMF. The broadcasting, publication or distribution of this communication in some countries may violate applicable laws and regulations. Therefore, physical persons in such countries and in countries in which this communication is broadest, published or distributed must enquire about any local restrictions and comply with them.

In particular:
This communication does note constitute an offer to buy or to subscribe, or an encouragement to buy or subscribe, to Genticel securities in the United States of America. Genticel securities may not be offered or sold in the United States of America, unless they have been registered or exempted from registration by the United States Securities Act of 1993, as amended (the "Securities Act"). Genticel's securities have not been and will not be registered under the Securities Act and Genticel has no intention of proceeding with any public offering of its shares in the United States of America.

This communication is promotional and does not constitute a prospectus in the sense of Directive 2003/71/EC of the European Parliament and Council of 4 November 2003, as amended (as transposed in any Member State of the European Economic Area) (the "Prospectus Directive").

As regards the Member States of the European Economic Area that have transposed the Prospectus Directive (a "Member State Concerned"), no action has been or will be taken to offer securities to the public that necessitates the publication of a prospectus in any Member State Concerned other than France. Consequently, shares in the Company can and will be able to be offered in those Member States Concerned only (i) to eligible investors as defined in the Prospectus Directive; (ii) to fewer than 100 investors, or if the Member State Concerned has transposed adequate provisions of the Modifying Prospectus Directive, 150 physical persons or legal entities (other than eligible investors as defined in the Prospectus Directive) to the extent permitted by the Prospectus Directive, or (iii) in any other circumstances that do not require the Company to publish a prospectus in accordance with Article 3(2) of the Prospectus Directive and/or the applicable regulations in the Member State Concerned, and provided that no other offers mentioned in paragraphs (i) to (iii) above do not require the Company to publish a prospectus in accordance with article 3 of the Prospectus Directive or a prospectus supplement in accordance with article 16 of the Prospectus Directive.

For the purposes of this disclaimer, the expression "public offering" concerning the shares of the Company in any Member State Concerned, means the communication in any form and in any manner whatsoever of enough information about the terms and conditions of the offer and about the shares to be offered to allow an investor to make a decision to buy or not buy those shares in the Company, as may be amended by the Member State Concerned regardless of how the Prospectus Directive had been transposed into the law of that Member State.

This communication does not contain or constitute an initiation, encouragement or incentive to invest. This communication is aimed in particular at people (i) who are not in the United Kingdom; (ii) who are not "investment professionals" in the sense of Article 19(5) of the French Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order"); (iii) who fall in the category of article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Order ; or (iv) to whom an invitation or incentive was offered to invest (in the sense of section 21 of the French Financial Services and Markets Act 2000) as part of issuing or selling marketable securities that may be legally communicated or were actually communicated. (These persons mentioned in (i), (ii), (iii) and (iv) referred to as "Eligible Persons".) This communication may not be used or relied upon by any unauthorised person. All investments and investing activities relating to this communication is reserved for Eligible Persons only.